# ALDH5A1

## Overview
The ALDH5A1 gene encodes the enzyme succinic semialdehyde dehydrogenase (SSADH), a mitochondrial enzyme that plays a pivotal role in the catabolism of gamma-aminobutyric acid (GABA), an essential neurotransmitter in the central nervous system. SSADH is categorized as an aldehyde dehydrogenase and is responsible for converting succinic semialdehyde into succinic acid, a critical step in the GABA metabolic pathway (RodríguezZavala2019Role; Muzio2012Aldehyde). The enzyme functions as a homotetramer and is characterized by its NAD+ cofactor-binding, catalytic, and oligomerization domains, which are crucial for its enzymatic activity and structural stability (Brennenstuhl2020Succinic; Tokatly2023Phenotypic). Mutations in the ALDH5A1 gene can lead to succinic semialdehyde dehydrogenase deficiency (SSADHD), a rare metabolic disorder with significant neurological implications (Malaspina2016Succinic; Brennenstuhl2020Succinic).

## Structure
The ALDH5A1 gene encodes the succinic semialdehyde dehydrogenase (SSADH) enzyme, which is crucial for the degradation of gamma-aminobutyric acid (GABA). The SSADH protein is a mitochondrial enzyme composed of 535 amino acids, with the first 47 residues forming a mitochondrial targeting sequence (Blasi2002Structure; Akaboshi2003Mutational). The protein structure includes several domains: an NAD+ cofactor-binding domain, a catalytic domain, and an oligomerization domain (Brennenstuhl2020Succinic; Tokatly2023Phenotypic).

The NAD+ binding domain is highly conserved and plays a significant role in the enzyme's structural integrity and stability, as well as in tetramer formation (Brennenstuhl2020Succinic). The catalytic domain features a dynamic catalytic loop with a reversible disulfide bond between Cys340 and Cys342, which acts as a redox switch to regulate substrate access (Brennenstuhl2020Succinic; Kim2009Redoxswitch). The enzyme functions as a homotetramer, with each monomer contributing to the overall quaternary structure (Menduti2018Succinic).

The ALDH5A1 gene also produces alternatively spliced isoforms, which may result in variations in the enzyme's structure and function (Blasi2002Structure). These structural features are essential for the enzyme's role in GABA catabolism.

## Function
The ALDH5A1 gene encodes the enzyme succinic semialdehyde dehydrogenase (SSADH), which plays a crucial role in the degradation of gamma-aminobutyric acid (GABA), an important neurotransmitter in the human brain. This enzyme is responsible for converting succinic semialdehyde into succinic acid within the mitochondrial matrix, a key step in the GABA metabolic pathway (RodríguezZavala2019Role; Muzio2012Aldehyde). The proper functioning of ALDH5A1 is essential for maintaining normal GABA levels, which is critical for neurological function and cellular energy production (Muzio2012Aldehyde).

In healthy human cells, ALDH5A1 activity prevents the accumulation of gamma-hydroxybutyric acid (GHB), a byproduct that can lead to neurodevelopmental abnormalities if not adequately metabolized (RodríguezZavala2019Role). The enzyme also contributes to detoxifying lipid peroxidation byproducts, although its role in the liver is considered marginal (RodríguezZavala2019Role). ALDH5A1's function is vital for maintaining cellular homeostasis and protecting against oxidative stress, which is important for the overall health and function of the nervous system (Muzio2012Aldehyde).

## Clinical Significance
Mutations in the ALDH5A1 gene, which encodes the enzyme succinic semialdehyde dehydrogenase (SSADH), lead to succinic semialdehyde dehydrogenase deficiency (SSADHD), a rare autosomal recessive disorder. This condition disrupts the degradation of gamma-aminobutyric acid (GABA), resulting in the accumulation of GABA and gamma-hydroxybutyric acid (GHB) in the brain and other tissues. Clinically, SSADHD is characterized by developmental delay, intellectual disability, hypotonia, epilepsy, and behavioral abnormalities, including autism spectrum disorder and sleep disturbances (Malaspina2016Succinic; Brennenstuhl2020Succinic; Pearl2009Succinic).

The disorder is diagnosed through biochemical analysis of GHB concentrations and confirmed by genetic testing of the ALDH5A1 gene. Pathogenic variants include missense, nonsense, and splicing mutations, with no major mutation hotspot identified (Malaspina2016Succinic; Didiasova2020Succinic). The severity of symptoms can vary widely, and there is no established correlation between specific genotypes and phenotypic severity (DiBacco2020Novel). Current treatments are symptomatic, focusing on managing epilepsy and behavioral issues, as no curative therapy exists (Brennenstuhl2020Succinic). Research into potential therapies, such as enzyme replacement and gene therapy, is ongoing (Brennenstuhl2020Succinic).

## Interactions
The ALDH5A1 gene encodes the enzyme succinic semialdehyde dehydrogenase (SSADH), which plays a crucial role in the GABA catabolism pathway. SSADH is a mitochondrial enzyme that functions as a tetramer, composed of identical monomers. The proper assembly of this tetrameric structure is essential for its enzymatic activity and stability (Tokatly2023Phenotypic). Variants in the ALDH5A1 gene can affect the oligomerization domain of the SSADH protein, disrupting its multimeric assembly and leading to functional impairments (Tokatly2023Phenotypic).

The enzyme's structure includes an NAD+ binding domain, a catalytic domain, and an oligomerization domain. Variants in these domains can lead to destabilization or misfolding, affecting the integrity of the NAD+ binding site and the overall protein structure (Tokatly2023Phenotypic). The His180Tyr variant, for example, retains high SSADH activity due to minimal structural perturbation, maintaining a crucial hydrogen bond necessary for tetramerization (Didiasova2024Functional).

While the context does not provide specific details on direct interactions with other proteins or nucleic acids, the role of SSADH in cellular metabolism suggests it may interact indirectly with nucleic acids through its involvement in metabolic pathways (Lee2022Understanding).


## References


[1. (Lee2022Understanding) Henry H. C. Lee, Gabrielle E. McGinty, Phillip L. Pearl, and Alexander Rotenberg. Understanding the molecular mechanisms of succinic semialdehyde dehydrogenase deficiency (ssadhd): towards the development of ssadh-targeted medicine. International Journal of Molecular Sciences, 23(5):2606, February 2022. URL: http://dx.doi.org/10.3390/ijms23052606, doi:10.3390/ijms23052606. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms23052606)

[2. (Brennenstuhl2020Succinic) Heiko Brennenstuhl, Miroslava Didiasova, Birgit Assmann, Mariarita Bertoldi, Gianluca Molla, Sabine Jung-Klawitter, Oya Kuseyri Hübschmann, Julian Schröter, Thomas Opladen, and Ritva Tikkanen. Succinic semialdehyde dehydrogenase deficiency: in vitro and in silico characterization of a novel pathogenic missense variant and analysis of the mutational spectrum of aldh5a1. International Journal of Molecular Sciences, 21(22):8578, November 2020. URL: http://dx.doi.org/10.3390/ijms21228578, doi:10.3390/ijms21228578. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms21228578)

[3. (Kim2009Redoxswitch) Yeon-Gil Kim, Sujin Lee, Oh-Sin Kwon, So-Young Park, Su-Jin Lee, Bum-Joon Park, and Kyung-Jin Kim. Redox-switch modulation of human ssadh by dynamic catalytic loop. The EMBO Journal, 28(7):959–968, March 2009. URL: http://dx.doi.org/10.1038/emboj.2009.40, doi:10.1038/emboj.2009.40. This article has 80 citations.](https://doi.org/10.1038/emboj.2009.40)

[4. (Blasi2002Structure) Paola Blasi, Pietro Pilo Boyl, Mario Ledda, Andrea Novelletto, K.Michael Gibson, Cornelis Jakobs, Boris Hogema, Shinjiro Akaboshi, Fabrizio Loreni, and Patrizia Malaspina. Structure of human succinic semialdehyde dehydrogenase gene: identification of promoter region and alternatively processed isoforms. Molecular Genetics and Metabolism, 76(4):348–362, August 2002. URL: http://dx.doi.org/10.1016/s1096-7192(02)00105-1, doi:10.1016/s1096-7192(02)00105-1. This article has 46 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s1096-7192(02)00105-1)

[5. (Akaboshi2003Mutational) Shinjiro Akaboshi, Boris M. Hogema, Andrea Novelletto, Patrizia Malaspina, Gajja S. Salomons, George D. Maropoulos, Cornelis Jakobs, Markus Grompe, and K. Michael Gibson. Mutational spectrum of the succinate semialdehyde dehydrogenase (aldh5a1) gene and functional analysis of 27 novel disease-causing mutations in patients with ssadh deficiency. Human Mutation, 22(6):442–450, November 2003. URL: http://dx.doi.org/10.1002/humu.10288, doi:10.1002/humu.10288. This article has 114 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.10288)

[6. (Menduti2018Succinic) Giovanna Menduti, Elisa Biamino, Roberta Vittorini, Serena Vesco, Maria Paola Puccinelli, Francesco Porta, Concetta Capo, Sara Leo, Bianca Maria Ciminelli, Federico Iacovelli, Marco Spada, Mattia Falconi, Patrizia Malaspina, and Luisa Rossi. Succinic semialdehyde dehydrogenase deficiency: the combination of a novel aldh5a1 gene mutation and a missense snp strongly affects ssadh enzyme activity and stability. Molecular Genetics and Metabolism, 124(3):210–215, July 2018. URL: http://dx.doi.org/10.1016/j.ymgme.2018.05.006, doi:10.1016/j.ymgme.2018.05.006. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ymgme.2018.05.006)

[7. (Pearl2009Succinic) P. L. Pearl, K. M. Gibson, M. A. Cortez, Y. Wu, O. Carter Snead, I. Knerr, K. Forester, J. M. Pettiford, C. Jakobs, and W. H. Theodore. Succinic semialdehyde dehydrogenase deficiency: lessons from mice and men. Journal of Inherited Metabolic Disease, 32(3):343–352, January 2009. URL: http://dx.doi.org/10.1007/s10545-009-1034-y, doi:10.1007/s10545-009-1034-y. This article has 91 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10545-009-1034-y)

[8. (Didiasova2024Functional) Miroslava Didiasova, Samuele Cesaro, Simon Feldhoff, Ilaria Bettin, Nana Tiegel, Vera Füssgen, Mariarita Bertoldi, and Ritva Tikkanen. Functional characterization of a spectrum of genetic variants in a family with succinic semialdehyde dehydrogenase deficiency. International Journal of Molecular Sciences, 25(10):5237, May 2024. URL: http://dx.doi.org/10.3390/ijms25105237, doi:10.3390/ijms25105237. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms25105237)

[9. (Malaspina2016Succinic) P. Malaspina, J.-B. Roullet, P.L. Pearl, G.R. Ainslie, K.R. Vogel, and K.M. Gibson. Succinic semialdehyde dehydrogenase deficiency (ssadhd): pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of gaba metabolism. Neurochemistry International, 99:72–84, October 2016. URL: http://dx.doi.org/10.1016/j.neuint.2016.06.009, doi:10.1016/j.neuint.2016.06.009. This article has 62 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.neuint.2016.06.009)

[10. (RodríguezZavala2019Role) José Salud Rodríguez-Zavala, Luis Francisco Calleja, Rafael Moreno-Sánchez, and Belem Yoval-Sánchez. Role of aldehyde dehydrogenases in physiopathological processes. Chemical Research in Toxicology, 32(3):405–420, January 2019. URL: http://dx.doi.org/10.1021/acs.chemrestox.8b00256, doi:10.1021/acs.chemrestox.8b00256. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1021/acs.chemrestox.8b00256)

[11. (Muzio2012Aldehyde) G. Muzio, M. Maggiora, E. Paiuzzi, M. Oraldi, and R.A. Canuto. Aldehyde dehydrogenases and cell proliferation. Free Radical Biology and Medicine, 52(4):735–746, February 2012. URL: http://dx.doi.org/10.1016/j.freeradbiomed.2011.11.033, doi:10.1016/j.freeradbiomed.2011.11.033. This article has 215 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.freeradbiomed.2011.11.033)

[12. (Didiasova2020Succinic) Miroslava Didiasova, Antje Banning, Heiko Brennenstuhl, Sabine Jung-Klawitter, Claudio Cinquemani, Thomas Opladen, and Ritva Tikkanen. Succinic semialdehyde dehydrogenase deficiency: an update. Cells, 9(2):477, February 2020. URL: http://dx.doi.org/10.3390/cells9020477, doi:10.3390/cells9020477. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells9020477)

[13. (Tokatly2023Phenotypic) Itay Tokatly Latzer, Jean-Baptiste Roullet, Samuele Cesaro, Melissa L. DiBacco, Erland Arning, Alexander Rotenberg, Henry H. C. Lee, Thomas Opladen, Kathrin Jeltsch, Àngels García-Cazorla, Natalia Juliá-Palacios, K. Michael Gibson, Mariarita Bertoldi, and Phillip L. Pearl. Phenotypic correlates of structural and functional protein impairments resultant from aldh5a1 variants. Human Genetics, 142(12):1755–1776, November 2023. URL: http://dx.doi.org/10.1007/s00439-023-02613-6, doi:10.1007/s00439-023-02613-6. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00439-023-02613-6)

[14. (DiBacco2020Novel) Melissa L. DiBacco, Ana Pop, Gajja S. Salomons, Ellen Hanson, Jean-Baptiste Roullet, K. Michael Gibson, and Phillip L. Pearl. Novel aldh5a1 variants and genotype: phenotype correlation in ssadh deficiency. Neurology, November 2020. URL: http://dx.doi.org/10.1212/wnl.0000000000010730, doi:10.1212/wnl.0000000000010730. This article has 18 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1212/wnl.0000000000010730)